{
      "id_number": "oai:ojs2.journal.urdti.uz:article/311",
      "type": "article",
      "full_text_status": "none",
      "uri": "https://arxiv.universalpublishings.com/id/eprint/52607",
      "date": "2026-02-14",
      "note": "Imported from URDTI Journal (OAI id oai:ojs2.journal.urdti.uz:article/311)",
      "ispublished": "pub",
      "date_type": "published",
      "metadata_visibility": "show",
      "official_url": "http://journal.urdti.uz/index/article/view/311",
      "subjects": [
        "proton nasos ingibitorlari",
        "GERK",
        "eroziv ezofagit",
        "peptik yara",
        "polifarmatsiya"
      ],
      "userid": 1,
      "publisher": "South Aral Region Medical Journal",
      "datestamp": "2026-05-26 15:45:45",
      "rev_number": 1,
      "creators": [
        {
          "name": {
            "honourific": null,
            "given": "Maxfirat",
            "lineage": null,
            "family": "Kibriyeva"
          }
        },
        {
          "name": {
            "lineage": null,
            "family": "Qurbonova",
            "honourific": null,
            "given": "Gulnoza"
          }
        }
      ],
      "eprintid": 52607,
      "title": "PROTON NASOS INGIBITORLARI (PPI)NI UZOQ MUDDAT QABUL QILISH: FOYDA\u2013XAVF BALANSI, NOO\u2018RIN BUYURILISH VA DEPRESKRIBING STRATEGIYALARI",
      "status_changed": "2026-05-26 15:45:45",
      "abstract": "Proton nasos ingibitorlari (PPI) gastroezofageal reflyuks kasalligi (GERK), eroziv ezofagit, peptik yara va ayrim yuqori GI qon ketish xavfi yuqori bemorlarda profilaktika uchun eng samarali antisekretor vositalardan hisoblanadi. Shu bilan birga, so\u2018nggi yillarda PPI\u2019larni uzoq muddat \u201cavtomatik\u201d davom ettirish, aniq ko\u2018rsatmasiz buyurish va polifarmatsiyani kuchaytirish holatlari ko\u2018paygani qayd etilmoqda. Bu tahliliy maqolada 2016\u20132025 yillardagi klinik qo\u2018llanmalar, amaliy tavsiyalar, randomizatsiyalangan tadqiqotlar hamda sistematik sharh va meta-tahlillar asosida PPI\u2019larning uzoq muddatli qo\u2018llanishida \u201cfoyda\u2013xavf\u201d balansi ko\u2018rib chiqildi. Asosiy e\u2019tibor noo\u2018rin buyurilish sabablari, uzoq muddatli davolashda uchrashi mumkin bo\u2018lgan nojo\u2018ya holatlar (rebound kislota gipersekresiyasi, enterik infeksiyalar, gipomagnezemiya, suyak salomatligi va buyrak bilan bog\u2018liq xavflar), shuningdek depreskribing (bosqichma-bosqich kamaytirish yoki to\u2018xtatish)ning amaliy strategiyalariga qaratildi. AGA best-practice bayonotlariga ko\u2018ra, PPI\u2019ni to\u2018xtatish qarori nojo\u2018ya hodisalardan \u201cqo\u2018rqish\u201d asosida emas, balki klinik ko\u2018rsatmaning mavjud-yo\u2018qligi va yuqori GI qon ketish xavfi baholangan holda qabul qilinishi kerak.\u00b9 Depreskribing muvaffaqiyatining kaliti \u2014 indikatsiyani hujjatlashtirish, yuqori xavf guruhlarini ajratish, bemorni rebound simptomlar haqida oldindan ogohlantirish hamda \u201ceng past samarali doza\u201d yoki \u201con-demand\u201d rejimiga o\u2018tishdir.",
      "lastmod": "2026-05-26 15:45:45",
      "publication": "South Aral Region Medical Journal",
      "eprint_status": "archive",
      "keywords": "proton nasos ingibitorlari; GERK; eroziv ezofagit; peptik yara; polifarmatsiya",
      "dir": "disk0/00/05/26/07",
      "sword_depositor": 1
    }